New vax tech drives fund-raising surge

Cash-hungry biotech companies have been headed back to the market recently as investors' appetite for biotech stocks was whetted by Big Pharma's high-profile pursuit of new therapies and the bright spotlight now focused on new vaccine technologies. Fund-raising has spiked 36 percent so far this year, says Thomson Reuters, with 39 debt offerings delivering $5.7 billion to an industry that has been starving for fresh capital. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.